Recent Updates
Recently added Catalysts
BHST Neutral Sentiment Score: 55/100

VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 - BioHarvest Sciences Inc.

Key Takeaway: BioHarvest Sciences Inc. has granted 5,400 Restricted Share Units and 111,998 stock options to employees and consultants, with a deemed issuance price of CAD $8.48 per share. The RSUs will vest after 12 months, while the stock options have various vesting terms extending up to 3 years. The company specializes in botanical synthesis aimed at creating therapeutic solutions and nutraceutical products. However, it has warned investors about the uncertainties surrounding future growth and profitability.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioHarvest granted RSUs and stock options, indicating employee investment.
  • The company is recognized for its patented botanical synthesis technology.
  • BioHarvest aims to develop science-based therapeutic solutions.

CONCERNS & RISKS

  • The announcement includes a caution about the uncertainties of forward-looking statements.
  • There is no assurance that contracts will materialize or lead to profitability.

Full Press Release Details

VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 - BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) announces that it has granted 5,400 Restricted Share Units ("RSUs") to an employee, with a deemed issuance price of CAD $8.48 per share unit. The RSUs will vest after 12 months.
Additionally, the Company has granted 111,998 stock options to consultants and employees. These options are exercisable for common shares of the Company at a price of CAD $8.48 per share, subject to the following vesting terms:
Stock Options Granted Vesting Terms Expiring Terms
4,430 Vesting quarterly over a 1-year period 10 Years
5,428 Vesting quarterly over a 2-year period 10 Years
102,140 Vesting quarterly over a 3-year period 10 Years
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) (NASDAQ: BHST) is a leader in botanical synthesis, leveraging its patented technology process to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Chief Executive Officer
Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622 -1186
Investor Relations Contact:
MZ Group - MZ North America (949) 259-4987
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts, and there is no assurance that signed agreements will progress past the first stage. Readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures which can be found under the Company's profile on www.sedarplus.ca.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

Frequently Asked Questions

What types of equity compensation has BioHarvest granted?

BioHarvest granted 5,400 RSUs and 111,998 stock options to employees and consultants.

What is the exercise price for the stock options?

The stock options are exercisable at CAD $8.48 per share.

When will the Restricted Share Units vest?

The RSUs will vest after a period of 12 months.

How are the stock options vested?

Stock options vest quarterly over periods of one to three years.

What is BioHarvest's focus in the biopharma sector?

BioHarvest specializes in botanical synthesis for therapeutic solutions and nutraceuticals.

Last updated: Nov 18, 2024